QIAGEN übertrifft Prognose für drottes Quartal 2024 with solid Wachstum and erhöht Jahresprognose for cleaningen Gain je Aktie

Q3 2024: Konzernumsatz of $502 million. (+5% for continuous courses, +6% for constant Wechselkursen, CER); Verwässerter Gewin is an Aktie of $0.44 and a bereinigter Verwässerter Gawin is an Aktie of $0.57 // Konzernumsatz at constant Wechselkursen (CER) of $502 Mio. übertrifft Prognose von mindestens $ 495 Mio. (CER); Bereinigter verwässerter Gainn je Aktie von $0.58 (CER) übertrifft Prognose von mindestens $0.55 (CER) // Diagnostics has started with 10% CER-Wachstum the strongest product group // Cleaning employee Margin has a 3 Prozentpointte on 29.6 % im Vergleich to 26.6% in Q3 2023 // Free cash flow increases in the first new month of 2024 to the previous quarter by 73% at $364 million. // Umsatzprognosis for Geschäftsjahr 2024 of at least $1,985 billion. (CER) upgraded solid Trends im Kerngeschäft bestätigt; Forecast for cleaning and washing Gain is an action at less than $ 2.19 (CER) higher

Venlo, Netherlands, November 06, 2024 (GLOBE NEWSWIRE) — QIAGEN NV (NYSE: QGEN; Frankfurt Prime Standard: QIA) has won the first month of the year 2024 in recent years.

The konzernumsatz was issued in the fourth quarter of 2024 by 5% on $502 million. In the past in the Vorjahreskwartaal, which is the great value of the constant Wechselkursen (CER), is 6% on $502 million. stay and forgive the $495 million forecast. (CER) delay. The company agent Marge had a large profit margin at 29.6%, making NeuMoDx-Systems’ profitability so high that all efficient investments could be reinvested and freed up. The profit you can make is that at $0.57 you are dealing with $0.58 (CER) and the forecast will only be $0.55 (CER).

For the Geschäftsjahr 2024, QIAGEN has a forecast for the Konzernumsatz of less than $1,985 Billion. (CER) op de Grundlage des Solid Kerngeschäfts in de rst new Monaten of de Jahres bekräftigt. The forecast for expected profit is an action based on $2.19 (CER) (€2.10 (CER) for a year beginning), assigning the forecast for the financial employee Margin of the mind 28.5% , shown at 26.9% in year 2023.

„QIAGEN has written a quarter that has created a solid Leistung design, through which we can see the Konzernumsatz and the bereinigten Gewinn-übertreffende konnten. The current situation was for all strong trends in our portfolios and the broader portfolios with 85% of stocks. Thanks to our different portfolios, the low, in that herausfordernden macro-economic environment of Quartal zu Quartal an Umsatzplus and a market-based profit, which ended with the Effizienz agent, zu ersoul,” says Thierry Bernard, Chief Executive Officer of QIAGEN.

“The first prize to win the Nobel Prize and the three QIAGEN Awards for its rapid improvement in the development of knowledge and the improvement of health care was the Stellenwert unseres Portfolios erneut unterstreicht. Unsere Teams improve our Portfolio further. You can perform the following tests on 100 new tests for the QIAcuity digital PCR system, which includes a new version of Clinical Testing Systems (QIAcuityDx). During the new pharmaceutical partnerships with AstraZeneca and Eli Lilly, we have completed the QIAstat-Dx-Systems application for syndromic testing. The Fortschritt at the Erreichung die Ziele in the year 2024 is a more important Schritt on the Road to the Umsetzung die Ziele for 2028 and unserem Bestreben nach einem soliden, profitable Wachstum,” says Bernard.

“Our economy in 2024 reflects a positive four-month trend in the development and the development of an economy that is a scaffolding of free cash flow is 73% wider. Because things have gone well, one of the activities for 2024 is a fact, and we will extend our vision of the company’s business activities,” said Roland Sackers, Chief Financial Officer of QIAGEN. “We set initiatives for the improvement of QIAGEN and the promotion of efficiency. This initiative puts us on the right track, an undisputed employee Marge bis Ende 2028 at 31% of the scaffolding. These efforts will explain a solidly profitable Wachstum.”

The complete press release incl. Tables can be found here.

General presentation and telephone conference

Bond Donnerstag, on November 7, 2024, at 3:30 PM MES / 2:30 PM GMT / 9:30 AM EST a telephone exchange has been installed. The conference call can be recorded as a live audio stream on the QIAGEN website and is then available for viewing. A hint presentation about the conference call on this page: https://corporate.QIAGEN.com/investor-relations/events-and-presentations/default.aspx.

Verwendung der bereinigten Ergebnisse

QIAGEN reports the bereinigten ergebnisse that the ergebnisse has adopted a constant law organization (CER) and other not nach US-GAAP (Generally Accepted Accounting Principles), one of the most likely financial matters included in the company’s financial sector. The large company is in charge of the works council, the company agent Marge, the works council, the works council for Steuern, the company I think you are active and achieve EBITDA, then The company is active, the company consists of shares, the company leads to price increases and free cash flow. Free cash flow is similar to the cash flow applied to the growth of the economy. Cleaning Ergebnisses sollten as zätzliche Information zur die messageseten Ergebnissehen set, which were set after GAAP, but not as ersatz für diese gewertet. QIAGEN is the insight that the best investments for the sale of goods are made, while the core history of the business lies, when periodic changes are made or the diversity of the experience, with the employees or with früheren Geschäft Periods beeinträchtigen. Use QIAGEN internally in planning, forecasting and reporting statistics to display and display Mitarbeitern-US-GAAP knowledge so that you can continuously acquire financial knowledge. If the work of the achievement is carried out with historical working ergebnisses, it may be that the basis is used to use QIAGEN as ergebnisse.

Uber QIAGEN

QIAGEN NV, a Dutch holding company, is a prosperous company engaged in extracting molecular molecular research from biological research. QIAGEN’s research technology ensures the processing and processing of DNA, RNA and proteins from Blut, Gewebe and other substances. Testing technology can perform this biomolecular analysis and analysis. Bioinformatics solutions and financial databases help interpret dating with more relevant and practically useful research. Automation integrations integrate these cost-effective testing workflows. QIAGEN makes more than 500,000 people available with the Bereichen Molekulare Diagnostik (Gesundheitsfürsorge) and Life Sciences (akademie Forschung, pharmakologische Fund und industrial Anwendungen, hauptsächlich Forensik) for Verfügung. Zum 30. September 2024 beschäftigte QIAGEN weltweit more than 5,800 employees in über 35 Standorten. More information about QIAGEN can be found at http://www.qiagen.com.

Forward-looking statement

Einige der Angaben in dieser Pressemitteilung im Sinne von Section 27A of the US Securities Act (US-Wertpapergesetz) von 1933 in ergänzter Fassung and Section 21E of the US Securities Exchange Act (US-Börsengesetz) von 1934 in ergänzter Fassung als zkunftsgerichttete Aussagen (‘forward ‘-looking statements”). Consider the notification of market-oriented products from QIAGEN, including the responses to the COVID-19 pandemic that produces products, the Zeitplan voor marktinführungen und Entwicklungen, regulische Genehmigungen, finanzielle und operative Prognosen, Wachstum , Expansion, Collaboration, Market, Strategy or operative enterprise were not limited to that of the erwartenden Ergebnisse voor de bereinigten Nettoumsatz und de bereinigten bewässerten Gewinn je Aktie, geschieht die op de Basis der Zeitiger Erwartungen en Annahmen, die met probabile auf dem Unsavory and risk-taking . This is the case: Risks in management and international management (einschließlich Auswirkungen von Währungsschwankungen und der Abhängigkeit von regulische sowie Logistikprozessen); Schwankungen der Betriebsergebnisse und je Verteilung auf unsere Kundengruppen; the market research for our products and knowledge in academic Research, Pharma, Testing and Molecular Diagnostics; Changes in our knowledge of our capabilities, our customers and our strategic partners, our knowledge and understanding of the environment, our technological progress, our knowledge of our quality and our QIAGEN products (einschließlich overall economics, quality and efficiency of our budgets and our budgets), that Möglichkeit, die regulatory products for our product, the quality of the products of QIAGEN, an integrated product and the regenlung-solcher products, the quality of the external products, new products to integrate, and the product of the law-bewerber to use who for the Wettbewerb zu schützen, Markttakzeptanz new products and integration requirements Geschäfte and technology; Maßnahmen von Regierungen; global or regional economic development; Wetter-oder transportbedingte Verzögerungen, Naturkatastrofen, politiken critique ou Krisen in het Bereichen van de Gesundheit, einschließlich des Ausmaßes und de Dauer der COVID-19-pandemic und die Auswirkungen op de Nachfrage nach unseren Producten und oder Aspekte unseres Geschäfts of sonstige Ereignisse höherer Gewalt ; so who has the power, as the erwartete Nutzen in the Zusammenhang with the young or anstehenden Acquisitionen, not who erwartet eintritt is; and other factors, discussed under “risk factors” in Absatz 3 des aktuellen Annual Report Form 20-F. More information can be found in messages sent by QIAGEN to the US Securities and Exchange Commission (US-Börsenaufsichtsbehörde).

Source: QIAGEN NV
Category: Financial

Contact us

Johannes Gilardi
+49 152 018 11711 / (email protected)

Domenica Martorana
+49 152 018 11244 / (email protected)

Dr. Thomas Theuringer
+49 2103 29 11826 / (email protected)

Lisa Specht
+49 2103 29 14181 / (email protected)

Quelle Hugin